Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines

Journal of Medicinal Chemistry

Volumn 53, Issue 10, 2010, Pages 4300-4304

  Arhancet, Graciela B ^a   Woodard, Scott S ^a   Dietz, Jessica D ^a   Garland, Danny J ^a   Wagner, Grace M ^a   Iyanar, Kaliappan ^a   Collins, Joe T ^a   Blinn, James R ^a   Numann, Randal E ^a   Hu, Xiao ^a   Huang, Horng Chih ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; EPLERENONE; ETHYL 5 CYANO 6 METHYL 2 PROPYL 4 QUINOLIN 4 YL 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; FELODIPINE; MEBUDIPINE; METHYL (2 CHLORO 4 FLUOROPHENYL) 2 (CHLOROMETHYL) 5 CYANO 6 METHYL 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; METHYL 2 (CHLOROMETHYL) 5 CYANO 6 METHYL 4 QUINOLIN 4 YL 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; METHYL 5 CYANO 2,6 DIMETHYL 4 QUINOLIN 4 YL 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; MINERALOCORTICOID RECEPTOR; NIFEDIPINE; TERT BUTYL 4 (2 CHLORO 4 FLUOROPHENYL) 5 CYANO 2,6 DIMETHYL 1,4 DIHYDROPYRIDINE 3 CARBOXYLATE; UNCLASSIFIED DRUG;

ARTICLE; CHIRALITY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; MOLECULAR MODEL; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY; X RAY CRYSTALLOGRAPHY;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DIHYDROPYRIDINES; GENES, REPORTER; HUMANS; LUCIFERASES; MODELS, MOLECULAR; PROTEIN BINDING; RATS; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952727090     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1002827     Document Type: Article

References (30)

1. Burt, V. L.; Whelton, P.; Roccella, E. J.; Brown, C.; Cutler, J. A.; Higgins, M.; Horan, M. J.; Labarthe, D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991 Hypertension 1995, 25 (3) 305-313
2. Hajjar, I.; Theodore, A.; Kotchen, T. A. Trends in Prevalence, Awareness, Treatand Control of Hypertension in the United States, 1988-2000 JAMA, J. Am. Med. Assoc. 2003, 290, 199-206
3. Williams, B. Drug Treatment of Hypertension Br. Med. J. 2003, 326, 61-62
4. Young, M.; Funder, J. W. Aldosterone and the Heart Trends Endocrinol. Metab. 2000, 11 (6) 224-226
5. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Barassin, C.; Marchais-Oberwinkler, S.; Hartmann, R. W. Heteroaryl-Substituted Naphthalenes and Structurally Modified Derivatives: Selective Inhibitors of CYR11B2 for the Treatment of Congestive Heart Failure and Myocardial Fibrosis J. Med. Chem. 2005, 48 (21) 6632-6642
6. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Marchais-Oberwinkler, S.; Hartmann, R. W. Synthesis and Evaluation of Heteroaryl-Substituted Dihydronaphthalenes and Indenes: Potent and Selective Inhibitors of Aldosterone Synthase (CYP11B2) for the Treatment of Congestive Heart Failure and Myocardial Fibrosis J. Med. Chem. 2006, 49 (7) 2222-2231
7. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming Undesirable CYP1A2 Inhibition of Pyridylnaphthalene-Type Aldosterone Synthase Inhibitors: Influence of Heteroaryl Derivatization on Potency and Selectivity J. Med. Chem. 2008, 51 (16) 5064-5074
8. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel Aldosterone Synthase Inhibitors with Extended Carbocyclic Skeleton by a Combined Ligand-Based and Structure-Based Drug Design Approach J. Med. Chem. 2008, 51 (19) 6138-6149
9. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In Vivo Active Aldosterone Synthase Inhibitors with Improved Selectivity: Lead Optimization Providing a Series of Pyridine Substituted 3,4-Dihydro-1 H -quinolin-2-one Derivatives J. Med. Chem. 2008, 51 (24) 8077-8087
10. Ries, C.; Lucas, S.; Heim, R.; Birk, B.; Hartmann, R. W. Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo J. Steroid Biochem. Mol. Biol. 2009, 116, 121-126
11. Hu, X.; Li, S.; McMahon, E. G.; Lala, D. S.; Rudolph, A. E. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone Mini-Rev. Med. Chem. 2005, 5 (8) 709-718
12. Pratt-Ubunama, M. N.; Nishizaka, M. K.; Calhoun, D. A. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering Curr. Hypertens. Rep. 2005, 7 (3) 186-192
13. Meyers, M. J.; Hu, X. Non-steroidal mineralocorticoid receptor antagonists Expert Opin. Ther. Patents 2007, 17 (1) 17-23
14. Dietz, J. D.; Du, S.; Bolten, C. W.; Payne, M. A.; Xia, C.; Blinn, J. R.; Funder, J. W.; Hu, X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity Hypertension 2008, 51 (3) 42-748
15. Fukumoto, S.; Ohra, T.; Sakamoto, J. Aldosterone Receptor Antagonists. PCT Int. Appl. WO2005097118, 2005.
16. Bossert, F.; Vater, W. 1,4-Dihydropyridines-a basis for developing new drugs Med. Res. Rev. 1989, 9 (3) 291-324
17. Rampe, D.; Kane, J. M. Activators of voltage-dependent L-type calcium channels Drug Dev. Res. 1994, 33 (3) 344-363
18. Shibanuma, T.; Iwanani, M.; Okuda, K.; Takenaka, T.; Murakami, M. Synthesis of optically active 2-(N -benzyl- N -methylamino)ethyl methyl 2,6-dimethyl-4-(m -nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate (nicardipine) Chem. Pharm. Bull. 1980, 28 (9) 2809-2812
19. Rovnyak, G. C.; Towart, R.; Wehinger, E.; Meyer, H. Effects of unsymmetrical ester substituted 1,4-dihydropyridine derivatives and their optical isomers on contraction of smooth muscle Naunyn-Schmiedebergs Arch. Pharmacol. 1981, 317 (2) 183-185
20. Kimball, S. D.; Beyer, B.; Cucinotta, G.; DiMarco, J. D.; Gougoutas, J.; Hedberg, A.; Malley, M.; McCarthy, J. P. Calcium Entry Blockers and Activators: Conformational and Structural Determinants of Dihydropyrimidine Calcium Channel Modulators J. Med. Chem. 1995, 38 (1) 119-129
21. Inagaki, O; Asano, M; Takenaka, T. In vitro and in vivo vasodilatory activity of barnidipine and its enantiomers Biol. Pharm. Bull. 1999, 22 (2) 151-156
22. Bohlooli, S.; Keyhanfar, F.; Mahmoudian, M. Pharmacokinetics of mebudipine, a new calcium antagonist, following single intravenous and oral administrations in rats Biopharm. Drug Dispos. 2004, 25 (4) 187-191
23. Loev, B.; Goodman, M. M.; Snader, K. M.; Tedeschi, R.; Macko, E. Hantzsch-type dihydropyridine hypotensive agents J. Med. Chem. 1974, 17 (9) 956-965
24. Alajarin, R.; Vaquero, J. J.; Garcia Navio, J. L.; Alvarez-Builla, J. Synthesis of 1,4- dihydropyridines under microwave irradiation Synlett. 1992, 4, 297-298
25. Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R. Novel procedure for modeling ligand/receptor induced fit effects J. Med. Chem. 2006, 49 (2) 534-553
26. Bledsoe, R. K.; Madauss, K. P.; Holt, J. A.; Apolito, C. J.; Lambert, M. H.; Pearce, K. H.; Stanley, T. B.; Stewart, E. L.; Trump, R. P.; Willson, T. M.; Williams, S. P. A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor J. Biol. Chem. 2005, 280 (35) 31283-31293
27. International Tables for X-Ray Crystallography; Kynoch Press: Birmingham, 1974; Vol. IV, pp 55 - 99, 149.
28. SHELXTL, version 5.1; Bruker AXS: Madison, WI, 1997.
29. Flack, H. D. On enantiomorph-polarity estimation Acta Crystallogr., Sect. A: Found. Crystallogr. 1983, 39, 876
30. Li, Y.; Suino, K.; Daugherty, J.; Xu, H. E. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor Mol. Cell 2005, 19 (3) 367-380